Peanut Allergy - Pipeline Review, H2 2015

Published: November 2015
No. of Pages: 67
   

Global Markets Direct’s, ‘Peanut Allergy - Pipeline Review, H2 2015’, provides an overview of the Peanut Allergy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peanut Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peanut Allergy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Peanut Allergy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Peanut Allergy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Peanut Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Peanut Allergy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Peanut Allergy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Peanut Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Peanut Allergy - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Peanut Allergy Overview 7
Therapeutics Development 8
Pipeline Products for Peanut Allergy - Overview 8
Pipeline Products for Peanut Allergy - Comparative Analysis 9
Peanut Allergy - Therapeutics under Development by Companies 10
Peanut Allergy - Therapeutics under Investigation by Universities/Institutes 11
Peanut Allergy - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Peanut Allergy - Products under Development by Companies 15
Peanut Allergy - Products under Investigation by Universities/Institutes 16
Peanut Allergy - Companies Involved in Therapeutics Development 17
BioLingus AG 17
BioTech Tools s.a. 18
DBV Technologies S.A. 19
HAL Allergy BV 20
Immunomic Therapeutics, Inc. 21
Peanut Allergy - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
aldesleukin - Drug Profile Product Description 31
Mechanism of Action 31
R&D Progress 31
Allergen for Peanut Allergy - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Allergen for Peanut Allergy - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AR-101 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ARA-LAMP-Vax - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
DBV-712 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
DN-1017 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Drugs to Inhibit PIM-1 Kinase for Respiratory and Immunological Diseases - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
PER-1080 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
pnut-ASIT - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Recombinant Protein for Peanut Allergy - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Recombinant Vector Vaccine for Peanut Allergy - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
VTC-064 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Peanut Allergy - Recent Pipeline Updates 47
Peanut Allergy - Dormant Projects 53
Peanut Allergy - Discontinued Products 54
Peanut Allergy - Product Development Milestones 55
Featured News & Press Releases 55
Nov 11, 2015: Aimmune Therapeutics Reports Positive Findings for ARC002 Follow-On Phase 2 Study of AR101 for Treatment of Peanut Allergy 55
Oct 07, 2015: Aimmune Therapeutics Receives EMA Decision Agreeing With PIP for AR101 for the Treatment of Peanut Allergy 56
Oct 05, 2015: Follow-Up Study of Viaskin Peanut Shows Significant Increase in Peanut Consumption and Treatment Benefit in Peanut Allergic Children 57
Jun 22, 2015: DBV Technologies Confirms Planned Initiation of Viaskin Peanut Global Phase III Clinical Trial in Children Following End-of-Phase II Meeting with FDA and PIP approval by EMA 59
Jun 18, 2015: Aimmune Therapeutics Receives FDA Breakthrough Therapy Designation for AR101 60
Jun 08, 2015: DBV Technologies Presents Clinical and Scientific Data at the EAACI Congress 61
Jun 07, 2015: Aimmune Therapeutics Announces Positive Phase 2 Study Results of AR101 for the Treatment of Peanut Allergy 62
Jun 04, 2015: DBV Technologies Announces EMA Pediatric Committee positive opinion on the Pediatric Investigation Plan for Viaskin Peanut for the Treatment of Peanut Allergic Children 64
Jun 03, 2015: Aimmune Therapeutics to Announce Phase 2 Data at EAACI Congress 2015 for Study of Peanut Allergy Desensitization Treatment 65
May 13, 2015: Immunomic Therapeutics Awarded $1.2M Department of Defense Grant for Development of ARA-LAMP-vax Peanut Allergy Vaccine 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables

Number of Products under Development for Peanut Allergy, H2 2015 8
Number of Products under Development for Peanut Allergy - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Comparative Analysis by Unknown Stage Development, H2 2015 14
Products under Development by Companies, H2 2015 15
Products under Investigation by Universities/Institutes, H2 2015 16
Peanut Allergy - Pipeline by BioLingus AG, H2 2015 17
Peanut Allergy - Pipeline by BioTech Tools s.a., H2 2015 18
Peanut Allergy - Pipeline by DBV Technologies S.A., H2 2015 19
Peanut Allergy - Pipeline by HAL Allergy BV, H2 2015 20
Peanut Allergy - Pipeline by Immunomic Therapeutics, Inc., H2 2015 21
Assessment by Monotherapy Products, H2 2015 22
Number of Products by Stage and Target, H2 2015 24
Number of Products by Stage and Mechanism of Action, H2 2015 26
Number of Products by Stage and Route of Administration, H2 2015 28
Number of Products by Stage and Molecule Type, H2 2015 30
Peanut Allergy Therapeutics - Recent Pipeline Updates, H2 2015 47
Peanut Allergy - Dormant Projects, H2 2015 53
Peanut Allergy - Discontinued Products, H2 2015 54

List of Figures

Number of Products under Development for Peanut Allergy, H2 2015 8
Number of Products under Development for Peanut Allergy - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Products, H2 2015 13
Assessment by Monotherapy Products, H2 2015 22
Number of Products by Targets, H2 2015 23
Number of Products by Stage and Targets, H2 2015 23
Number of Products by Mechanism of Actions, H2 2015 25
Number of Products by Stage and Mechanism of Actions, H2 2015 25
Number of Products by Routes of Administration, H2 2015 27
Number of Products by Stage and Routes of Administration, H2 2015 27
Number of Products by Molecule Types, H2 2015 29
Number of Products by Stage and Molecule Types, H2 2015 29

Published By: Global Markets Direct
Product Code: Global Markets Direct13884


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we´┐Żll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: